The US Food and Drug Administration still refuses to acknowledge that e-cigarettes could be a healthier alternative to traditional cigarettes, even though many other parts of the world are actively encouraging smokers to use e-cigarettes more safely.
The agency, which had an outbreak of fog-related lung injuries and deaths this summer, urged the public to completely stop using the device until it knew more about the cause of the illness, even though all confirmed links to illegal electronic liquids purchased.
Now, the agency is taking a similar approach with marijuana and the non-psychotic compound cannabidiol, or CBD, found in marijuana, reiterating that not only is it illegal to use CBD in food or as a supplement, but it exists as well.
The results of both actions were predictable: some e-cigarette companies have been crushed by the market.
The future of CBD is still cloudy
The FDA acknowledges the benefits of marijuana and marijuana compounds like CBD, but warns consumers not to assume they are safe. The agency did approve A CBD-containing drug, GW Pharmaceutical's (NASDAQ: GWPH) Epilodex, to treat two rare conditions. But even drug-grade compounds in Epilodex expose users to potential side effects, including liver damage, reactions to other drugs and damage to male reproductive function.
The potential consequences of using over-the-counter CBD preparations remain unclear, especially when people use them in combination across multiple uses, such as in food products and topical creams. The effect on certain populations, such as the elderly, children and even lactating mothers, is not yet known.
That's not entirely worrisome, especially since the FDA says it wants to use a science-based approach to approving products and needs to be cautious when it comes to public health. It says it wants consumers to know the facts before using CBD products.
However, regulators have not moved quickly to develop a clear policy on CBD, while consistently citing the risks associated with CBD, leading to a scale against it. It could be years before official policy becomes more balanced.
This is not unlike the case with e-cigarettes, which are generally considered a safer, healthier option for smokers. The FDA has yet to label any devices as risk-reducing (though it did approve Swedish Match's brand of snuff, a moist, powdery tobacco product).
Although the agency's advisory panel recommended that Philip Morris International inc. 's (NYSE: PM) non-burning e-cigarettes be approved for risk reduction labeling, the FDA's three-year absence of action on the issue came months before the marketing application was filed.
Instead, the FDA has spent much of its time taking up the task of reporting an uptick in teen e-cigarette use across the industry, and has targeted leading manufacturer Juul Labs for scrutiny. Investors also applauded altria Group, which was forced to write down more than a quarter of the value of its $12.8bn investment in the e-cigarette maker. The agency also proposed banning all flavored e-cigarette oils, even if adults use flavors to help them transition from smoking.
Rather than encouraging smokers to switch to e-cigarettes, the FDA has made it clear that it considers any use of nicotine to be harmful and has set up an expensive maze of approval procedures (so far, only the two biggest tobacco giants have managed to submit applications for review). The industry's deadline is May 2020, suggesting that many industries won't make it.
While no e-cigarette maker has been caught up in the health scare, the company has also used the outbreak of lung disease to heighten its antipathy to the industry.

